News
-
October 29, 2020
Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing autoimmune disease, today announced that it will report its third quarter 2020 financial...
-
October 01, 2020- Healthcare professional and patient campaigns focus on screening for early-stage T1D-
Provention Bio, Inc. (Nasdaq:PRVB), a biopharmaceutical company dedicated to intercepting and preventing autoimmune disease, yesterday launched a national effort to redefine patient care in type 1...
-
September 30, 2020- Expect to complete filing of the rolling Biologics License Application (BLA) submission for teplizumab in Q4 2020 -
Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced the submission of the clinical module of the...
-
September 08, 2020
Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that management will present at three upcoming...
-
August 31, 2020Potential to be the first approved therapeutic for the treatment of Non-responsive Celiac Disease
Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced the initiation of the Phase 2b PROACTIVE...